A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)
Change from baseline in the morning pre-dose forced vital capacity (FVC) (mL) at Week 12
Endpoint detail
Time to disease progression. Disease progression is defined as FVC percent predicted decline of ≥10% prior to Week 12, respiratory hospitalization, or death., Change from baseline in quantitative lung fibrosis metrics on HRCT at Week 12
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.